2010-04-20
Interim Report – January to March 2010
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company
focused on developing next generation products for therapy, diagnostic imaging, and other
applications based on its unique proprietary technology platforms: Affibody® molecules
and AlbumodTM, today issued its Interim Report covering the First Quarter 2010.
2010-02-19
Year-End Report 2009
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company
focused on developing next generation products for therapy, diagnostic imaging, and other
applications based on its unique proprietary technology platforms: Affibody® molecules
and AlbumodTM, today issued its Year-End Report for 2009.
2009-12-01
Interim Report - January to September
Interim Report – January to September 2009
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company
focused on developing next generation products for therapy, diagnostic imaging, and other
applications based on its unique proprietary technology platforms: Affibody® molecules
and AlbumodTM, today issued its Interim Report covering the nine-month period ended
September 30, 2009.
2009-08-26
Interim Report - January to June 2009
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company
focused on developing next generation products for therapy, diagnostic imaging, and other
applications based on its unique proprietary technology platforms: Affibody® molecules
and AlbumodTM, today issued its Interim Report covering the First Half of 2009.
2009-07-01
Imaging Technique Allows Researchers to Monitor Protein Changes in Mouse Tumors
A new imaging technique can monitor, in living mice, the HER2 protein found in above-normal amounts in many cases of breast cancer as well as some ovarian, prostate and lung cancers. This new approach, once validated in mice and pending further experiments, could provide a real-time noninvasive method for identifying tumors in humans who express HER2 and who would be candidates for targeted therapy directed against this protein. It may also provide real-time information that will help clinicians optimize treatment for individual patients. The study, published in the July 2009 issue of The Journal of Nuclear Medicine, was conducted by researchers at the National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering, both parts of the National Institutes of Health.
2009-04-29
Interim Report - January to March 2009
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company
focused on developing next generation products for therapy, diagnostic imaging, and other
applications based on its unique proprietary technology platforms: Affibody® molecules
and albumin binding technology, today issued its Interim Report covering the First Quarter
2009.
2009-03-24
Biovitrum gets access to Affibody® Technology
Affibody AB today signed a collaboration agreement with Biovitrum AB (publ) (STO:BVT) with the aim of developing new targeted therapeutics for inflammation and autoimmune diseases.
2009-02-23
Year-End Report 2008
Affibody Holding AB (publ) (“Affibody” or “the Company”) today issued its year-end 2008
report. Affibody is a Swedish biotech company focused on developing next generation
products for therapy, diagnostic imaging, and other applications based on its unique
proprietary technology platforms: Affibody® molecules and albumin binding technology.